Retired
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Farm: I agree it certainly looks bleak. All the stocks I track are in the same boat. I guess those in control of the market are all short sellers; otherwise surely there would be an outcry. Our whole nation is in free fall.
Opti
John, John, John, have you failed your stockholders once again, simply by failing to update financials? What goes thru the mind of a criminal, a deceiver? Do you truly not fear God? Do you truly not believe you will one day be held accountable?
Opti
News Release Issued: Mar 15, 2022 (9:30am EDT)
To view this release online and get more information about Newsroom | Co-Diagnostics, Inc. visit: https://news.codiagnostics.com/2022-03-15-Co-Diagnostics,-Inc-Announces-Authorization-of-30-Million-Share-Repurchase-Program
Co-Diagnostics, Inc. Announces Authorization of $30 Million Share Repurchase Program
SALT LAKE CITY, March 15, 2022 /PRNewswire <http://www.prnewswire.com/> / --?Co-Diagnostics, Inc.?(Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its Board of Directors has authorized a share repurchase program that would allow the Company to repurchase up to $30 million of CODX common stock.
<https://mma.prnewswire.com/media/1141654/Co_Diagnostics_Official_Logo.html>
"This share repurchase program is aligned with our commitment to return value to our shareholders and reflects confidence in our balance sheet and strong cash flow generation," remarked Brian Brown, Chief Financial Officer of Co-Diagnostics. "We believe that the current share price provides us with an opportunity to strategically allocate capital in a way that helps drive continued growth and demonstrates our positive outlook for the Company's future."
The repurchase program does not obligate the Company to acquire any particular amount of common shares, and the repurchase program may be suspended or discontinued at any time at the Company's discretion. The timing and amount of any share repurchases under the share repurchase program will be determined by Co-Diagnostics' management at its discretion based on ongoing assessments of the capital needs of the business, the market price of the Company's common stock, corporate and regulatory requirements, and general market conditions. Share repurchases under the program may be made through a variety of methods, which may include open market purchases, in block trades, accelerated share repurchase transactions, exchange transactions, the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, or any combination of such methods.
I wonder when John will submit the Financials?
Opti
Co-Diagnostics: Swinging For The Fences
Jan. 24, 2022 8:19 AM ETCo-Diagnostics, Inc. (CODX)2 Likes
Summary
Seeking Alpha's three ratings metrics have long awarded Co-Diagnostics top grades of "A+".
Shareholders have been unimpressed as its shares have underperformed despite increasing sales.
If its Eikon system pans out, Co-Diagnostics will be an investment for the ages.
https://seekingalpha.com/article/4481153-co-diagnostics-swinging-for-fences?messageid=2800&utm_campaign=4481153&utm_medium=email&utm_source=seeking_alpha&utm_term=RTA+Article+Smart
Opti
$CODX Providing 5 Million Additional Lab-Based PCR Tests for Free to Schools Per Month: The Administration is making available lab capacity to support an additional 5 million PCR tests per month for schools to perform individual and pooled testing in classrooms nationwide. The additional testing will be delivered through the Department of Health and Human Services’ (HHS) Operation Expanded Testing (ET) program, funded by the American Rescue Plan to provide free PCR testing at schools nationwide. Three federally funded regional providers offer testing materials, supplies, and lab results and reporting at no direct cost to recipients through four regional hubs. Schools can immediately gain access to this free lab-based testing. https://www.whitehouse.gov/briefing-room/statements-releases/2022/01/12/fact-sheet-biden-harris-administration-increases-covid-19-testing-in-schools-to-keep-students-safe-and-schools-open/
Opti
$CODX
why is it we know so few of the details about this company? Where are the clinical trials for Eikon being performed? What are the trial parameters? When will they be concluded? What is the status of contracts? Has CODX applied for a contract with the Biden Administration for development of Eikon? What plans are there for expansion? Has the company ever received a buyout offer? So many questions; no apparent analysts asking the company.
People ask why Yooo keeps posting negative comments on J Campo and his companies. The reason is to balance the posts of those that keep saying the financials will be filed soon and the stock will recover. We have been down this road before with NEWC. The financials will never be filled. The ticker will be delisted. And John will once again pocket the cash and move on to his next scam. Sad.
Opti
$CODX A contract for development of Eikon would be great as it would affirm the development and give us a schedule. That would settle the uncertainty that is holding the PPS at current levels. Opti
this is why we need the ABC test
https://www.cnn.com/2021/12/28/health/is-it-cold-flu-or-covid-wellness/index.html
Opti
Unbelievable
Why Co-Diagnostics Stock Rose 15.8% on Monday
The molecular testing company is expected to benefit from the rise in cases of the omicron COVID-19 variant.
Jim Halley
Dec 27, 2021 at 4:21PM
Key Points
The company, through nine months, has seen revenue rise by 63.4% year over year.
Co-Diagnostics is developing an at-home COVID-19 test.
Motley Fool Issues Rare “All In” Buy Alert
What happened
Co-Diagnostics (NASDAQ:CODX) saw its shares rise 15.8% on Monday. The molecular diagnostics company, which closed at $9.41 on Thursday, opened at $9.50 on Monday and rose to $10.90 shortly after noon. The company is up more than 9.9% for the year. The stock is still closer to its 52-week low of $7.01 than its 52-week high of $20.68.
So what
The company didn't have any breaking news, but the continued rise in the omicron COVID-19 variant buoyed the company's stock. The company also announced last week that it is near to releasing its at-home COVID-19 test.
It's been a big year for Co-Diagnostics, thanks to its group of COVID-19 polymerase chain reaction (PCR) diagnostic assays. Last month, the company said its revenue through nine months was $77.5 million, up 63.4% year over year, adding that it expected full-year revenue of $96 million to $100 million, compared with $74.55 million last year. The company's reported net income through nine months of $29.2 million represents a drop of 1.7% over the same period last year, but the company is still on track for a second consecutive year in the black and its second profitable year since its initial public offering in 2017. Most of its $30.1 million revenue (89%) in the quarter was due to sales of its Logix Smart COVID-19 test, Co-Diagnostics said.
One reason for the lowered net income is the company just purchased Idaho Molecular and Advanced Conceptions with 4.72 million shares of stock to help it ramp up its at-home Eikon testing platform and YourTest PCR device for its market release, possibly in the first quarter of 2022. The company said it expects the deal to close by the end of this year, and both companies will be subsidiaries of Co-Diagnostics.
Though the Food and Drug Administration has yet to approve the test, the point will be for the Eikon platform to use nasal swab and saliva samples to test for COVID-19 and other diseases. Co-Diagnostics CEO Dwight Egan said, in the third-quarter report, that the company is shooting for affordable PCR tests at point-of-care and at-home settings to help slow the spread of COVID.
Now what
Co-Diagnostics' rise has been due almost entirely to the need for increased testing for COVID-19. While recent events show that the disease may not go away anytime soon, the biotech company will still need to extend its revenue streams to be a good long-term stock. It has shown it is looking to do that with multi-use tests. While the stock certainly has risks, it doesn't appear to be overpriced, with a forward price-to-earnings ratio of 9.633.
Co-Diagnostics at a three-month high extending post-merger gains
Dec. 27, 2021 3:17 PM ETCODXBy: Dulan Lokuwithana, SA News Editor1 Comment
Success business chart with green arrow up and USA dollars background. Profit and money. Financial and business graph. Stock market growth 3d illustration.
JuSun/iStock via Getty Images
Co-Diagnostics (CODX +12.1%) shares are trading at the highest level since mid-September after the company announced a transaction under which Advanced Conceptions and Idaho Molecular will become two of its subsidiaries.
On Dec 21, the company has struck two separate agreements and plans of mergers with its wholly-owned subsidiaries, Advanced Conceptions Acquisition and IDMO Acquisition, to make Advanced Conceptions and Idaho Molecular two of its own subsidiaries, respectively.
In addition, on Wednesday, Co-Diagnostics (NASDAQ:CODX) disclosed an update to the company’s Joint Development & License Agreement signed with Advanced Conceptions in February for an at-home/point-of-care testing device. Per the terms, Advanced Conceptions has subcontracted several of its obligations to Idaho Molecular.
A maker of PCR tests for the diagnosis of COVID-19, Co-Diagnostics (CODX) has traded higher in line with today’s gains of test makers.
$CODX next four big steps: 1. announcement of major testing contract with government. 2. submission of Eikon for approval. 3. announcement of approval of ABC test. 4. approval of Eikon. Care to guess the dates of each? Opti
Look for contracts next week
The Biden administration is currently trying to ramp up testing across the US in light of the highly infectious Omicron variant, which has affected unvaccinated people as well as those who had been vaccinated or received their booster shots.
However, in the early months of the Biden presidency, the administration had made COVID-19 testing a priority as they thought it was the best way to stop the spread of the virus, current and former US officials told The Post.
Officials were particularly keen on widespread PCR testing as there was greater doubt over the accurate of rapid antigen tests at the time, the sources told The Post.
A Centers for Disease Control and Prevention-led report released on January 1 found that rapid antigen tests were substantially less accurate than PCR tests.
However, the Biden administration's focus on testing was suddenly replaced by a focus on vaccines after modeling at the time showed they were the best way to drive down infections, The Post said.
"They were like, 'Great. We can vaccine our way out of this thing, so we don't need so many tests,'" a former transition official told The Post.
Biden admin abandoned work on a mass COVID-19 testing plan because it thought it could 'vaccine our way out of' the pandemic, report says (msn.com)
Reuters analysis on ETrade now at 10, "one of only 213 stocks awarded this highest score of 10." "The recent change in the Average Score was primarily due to an improvement in the Earnings and Price Momentum component scores." 2021 December 22.
Opti
Biden administration tells COVID-19 test manufacturers that demand for tests could double or triple in coming months with Omicron variant https://news.yahoo.com/biden-administration-tells-covid-19-031925982.html
Opti
As my mom always says, So's Christmas.
Opti
Hard to figure this one out. I originally connected my account then thought better and took the link away. Dividend or stock buyback would be better.
Holding long.
Opti
Why would you possibly WANT to buy share of a stock certain to be delisted.
Vanguard Group Inc. increased its position in shares of Co-Diagnostics, Inc. (NASDAQ:CODX) by 1.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,848,637 shares of the company’s stock after purchasing an additional 18,163 shares during the period. Vanguard Group Inc. owned approximately 6.45% of Co-Diagnostics worth $15,251,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also recently added to or reduced their stakes in the stock. Nuveen Asset Management LLC lifted its holdings in Co-Diagnostics by 14.2% during the 1st quarter. Nuveen Asset Management LLC now owns 791,920 shares of the company’s stock worth $7,555,000 after purchasing an additional 98,358 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Co-Diagnostics by 11.4% during the 1st quarter. Geode Capital Management LLC now owns 435,514 shares of the company’s stock worth $4,154,000 after purchasing an additional 44,417 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in Co-Diagnostics by 47.9% during the 2nd quarter. Russell Investments Group Ltd. now owns 253,917 shares of the company’s stock worth $2,094,000 after purchasing an additional 82,187 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in Co-Diagnostics by 8.3% during the 1st quarter. Principal Financial Group Inc. now owns 162,333 shares of the company’s stock worth $1,549,000 after purchasing an additional 12,385 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in Co-Diagnostics by 3.9% during the 1st quarter. Bank of New York Mellon Corp now owns 155,561 shares of the company’s stock worth $1,484,000 after purchasing an additional 5,806 shares during the last quarter. 25.61% of the stock is owned by institutional investors and hedge funds.
ADOMANI misses on revenue
Nov. 11, 2021 4:24 PM ETEnvirotech Vehicles, Inc. (ADOM)By: Jignesh Mehta, SA News Editor1 Comment
ADOMANI (OTCQB:ADOM): Q3 net loss of $0.85M.
Revenue of $0.7M misses by $0.1M.
ADOMANI misses on revenue
Nov. 11, 2021 4:24 PM ETEnvirotech Vehicles, Inc. (ADOM)By: Jignesh Mehta, SA News Editor1 Comment
ADOMANI (OTCQB:ADOM): Q3 net loss of $0.85M.
Revenue of $0.7M misses by $0.1M.
CODX After-Hours Quotes L
Data last updated Nov 11, 2021 04:33 PM ET.
Consolidated Last Sale $9.85 +1.20 (+13.87%)
After-Hours Volume 444,710
After-Hours High $10.16 (04:05:51 PM)
After-Hours Low $8.86 (04:01:03 PM)
Co-Diagnostics EPS beats by $0.17, beats on revenue
Nov. 11, 2021 4:02 PM ETCo-Diagnostics, Inc. (CODX)By: Gaurav Batavia, SA News Editor
Co-Diagnostics (NASDAQ:CODX): Q3 GAAP EPS of $0.38 beats by $0.17.
Revenue of $30.1M (+37.9% Y/Y) beats by $5.78M.
Press Release
Full Year 2021 Outlook:Co-Diagnostics is offering the following guidance for its full year of 2021:
Revenue to be in the range of $96.0 million to $100.0 million vs. $23.52M consensus.
Diluted earnings per share forecasted to be in the $1.07 to $1.16 range vs. $0.14 consensus, with shares outstanding expected to be approximately 30 million and a corporate effective tax rate of approximately 18.0%.
Co-Diagnostics EPS beats by $0.17, beats on revenue
Nov. 11, 2021 4:02 PM ETCo-Diagnostics, Inc. (CODX)By: Gaurav Batavia, SA News Editor
Co-Diagnostics (NASDAQ:CODX): Q3 GAAP EPS of $0.38 beats by $0.17.
Revenue of $30.1M (+37.9% Y/Y) beats by $5.78M.
Press Release
Full Year 2021 Outlook:Co-Diagnostics is offering the following guidance for its full year of 2021:
Revenue to be in the range of $96.0 million to $100.0 million vs. $23.52M consensus.
Diluted earnings per share forecasted to be in the $1.07 to $1.16 range vs. $0.14 consensus, with shares outstanding expected to be approximately 30 million and a corporate effective tax rate of approximately 18.0%.
Co-Diagnostics Reports Continued Strength in Third Quarter 2021 Financial Results
Solid quarterly results highlighted by record revenue of $30.1 million, pre-tax income of $13.6 million and fully diluted EPS of $0.38
VSYM
VIEW SYS INC COM NEW
$0.0001-0.0001 (-50.00%)
Bid x Size
-- x --
Ask x Size
-- x --
YOOO: Send me an email at jpaul7212@gmail.com
Opti
Wish we could see a reflective pps.
Opti
Yooo: send me an email at jpaul7212@gmail.com.
Opti
check out the posts by Yoo and Optimist. We know Campo is a liar and we have posted this consistently.
Sorry for your loss.
Opti
John did this with me on NEWC for over a year. Many promises and none kept. I don't know how he has survived the past 5 years.
Opti
Campo submit his Financials yet?
LOL
opti
He said that probably 20 times on NEWC over a two-year period. Promises, just hang in there.
Never happened; never completed the financials. Never submitted the stock for re-registration. All lies.
And he is doing it again.
Opti
That's a fact.
Opti
Nomi Health Actively Hiring More Than 200 Staff for TestUtah Mobile Testing Initiative via Expanded Partnership With the State
Nomi’s COVID response platform is also used effectively in Iowa, Nebraska, Florida, Hawaii, Texas, Alabama and Colorado. The company uses U.S. Food & Drug Administration-authorized tests from Co-Diagnostics, Inc., and maintains the highest standards with ISO 270001, FedRAMP, HITRUST and HIPAA-compliant technology, and testing site materials. At the peak of COVID, Nomi was responsible for performing more than 50,000 tests a day throughout the nation.
Opti
March of 2020
As you know, I'm also the chairman of View Systems, Inc. (VSYM), which has made some investments/loan to NCR to further develop. To that end, I'm contemplating the possibility of an acquisition scenario where NCR shareholders could get VSYM once I clean it up. The current path of waiting for audits is still in motion, only I have to get payment to accountant for 2019, for now this is still the plan.
Once I'm able to get investors to purchase the assignment of existing VSYM notes and stop conversions, that will bode well for NCR.
Will keep you posted, stay safe,
John